Skip to main content
logo
Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
3.480
+0.040 (1.16%)
Aug 25, 2026, 4:00 PM EDT - Market closed

Voyager Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
34.4640.3780250.0140.9137.42
Revenue Growth
-19.07%-49.53%-68.00%511.16%9.33%-78.14%
Gross Profit
-81.6-91.9-44.59157.84-14.86-36.37
Operating Income
-113.69-128.34-80.51122.01-45.84-73.62
Net Income
-107.73-119.72-65132.33-46.41-71.2
Earnings Per Share
-1.81-2.04-1.132.97-1.21-1.89
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
148.81201.69332.39230.88118.85132.54
Total Debt
32.5736.543.7320.2923.1344.18
Net Cash (Debt)
116.25165.19288.66210.5895.7288.36
Net Cash Growth
-47.60%-42.77%37.08%119.99%8.33%-33.83%
Net Cash Per Share
1.962.815.014.722.502.35

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-120.57-132.47-15.3177.92-12.51-53.53
Capital Expenditures
-0.85-2.6-3.52-3.26-2.49-1.61
Free Cash Flow
-121.42-135.06-18.8374.66-15-55.13
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-236.81%-227.62%-55.74%63.13%-36.32%-97.21%
Operating Margin
-329.92%-317.89%-100.64%48.80%-112.05%-196.76%
Pretax Margin
-312.26%-296.17%-80.42%53.49%-113.41%-190.29%
Profit Margin
-312.63%-296.53%-81.25%52.93%-113.45%-190.29%
FCF Margin
-352.36%-334.53%-23.54%29.86%-36.67%-147.36%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
---2.81--
P/FCF Ratio
---4.97--
PS Ratio
6.225.413.871.495.762.75